EAN Research Paper of the Month
Research Paper of the Month – March: Mood Alterations in the Prodromal Phase of Sporadic Creutzfeldt-Jakob Disease.
Creutzfeldt-Jakob disease (CJD) is a rare and rapidly progressive neurodegenerative disease caused by misfolded prion proteins, which lead to neuronal loss and spongiform encephalopathy. Despite significant research efforts, the etiology and the pathogenesis of sporadic CJD (sCJD) remain unclear. Its short survival period, rarity, and wide-ranging symptoms pose significant challenges to identifying potential risk factors or triggers. Moreover, overlapping health conditions and atypical symptoms often hinder antemortem diagnosis.
Research Highlights of the Month – March 2025
Research Paper of the Month – February: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK
To view the EAN report click here
To access the full Lancet article click here
For Research highlights of the month click here
To view other EAN Research Papers of the Month see below
| Month | Paper title | Description |
|---|---|---|
| September | Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission | The number of people living with dementia is steadily rising, making it more urgent than ever to identify and implement effective prevention strategies. This work updates the 2020 Lancet Commission report in which twelve risk factors for dementia were identified, using a life-course approach: i.e., less education, hearing loss, hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, and social isolation. In this recently published report, two more risk factors, i.e. untreated vision loss and high LDL cholesterol, have been added as risk factors for dementia in midlife and late life, respectively. To view the EAN report click here |
| October | A Monoclonal Antibody to PACAP for Migraine Prevention | Migraine is a debilitating neurological disorder affecting over a billion people globally, with current preventive repurposed treatments, like beta-blockers and antiseizure drugs, often yielding inadequate results or adverse side effects. Even the newer migraine-specific approach of targeting the calcitonin gene-related peptide (CGRP) still leaves around 40 to 70% of patients without sufficient relief. To view the full paper please click Here |
| November | Safety and efficacy of evobrutinib in relapsing multiple sclerosis | Inflammation and neurodegeneration in the central nervous system (CNS) of multiple sclerosis (MS) patients drive neuronal damage, brain atrophy and disability. Bruton’s tyrosine kinase (BTK) is a key player in B cell signalling, as well as in other immune cells like monocytes, macrophages, and microglia. BTK inhibitors not only suppress B cells but also target CNS innate immune cell inflammation by affecting microglia and macrophages. Evobrutinib, a highly selective BTK inhibitor, showed encouraging clinical and imaging effects in a phase 2 trial for relapsing MS. For the full paper please click Here |
| December |
